Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows:
wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.
On the Tautomerism of Cinnolin-4-ol, Cinnolin-4-thiol, and Cinnolin-4-amine
作者:Wolfgang Holzer、Gernot A. Eller、Simeon Sch嗜berger
DOI:10.3987/com-07-11177
日期:——
Detailed NMR spectroscopic investigations ((1)H, (13)C, (15)N) with cinnolin-4-ol (1) reveal this compound to exist exclusively in the 77 cinnolin-4(1H)-one form in deuteriodimethyl sulfoxide solution. This finding is confirmed by comparison of the NMR spectroscopic data of 1 with those of the corresponding 'fixed' O-methyl and N-methyl derivatives, i.e. 4-methoxycinnoline (3) and 1-methylcinnolin-4(1H)-one (5). Similarly, cinnoline-4-thiol (4) is present in the thione form in deuteriodimethyl sulfoxide, whereas cinnolin-4-amine (7) exists in the amino form. In addition, in-depth analyses of the NMR spectra of some simple 4-substituted cinnolines are provided.
86. Cinnolines. Part XXVI. Some 4-cinnolylhydrazines, their preparation and oxidation. Miscellaneous quinoline derivatives
作者:K. Schofield、T. Swain
DOI:10.1039/jr9500000392
日期:——
Alder; Niklas, Justus Liebigs Annalen der Chemie, 1954, vol. 585, p. 97,109
作者:Alder、Niklas
DOI:——
日期:——
[EN] PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLE EN TANT QU'INHIBITEURS DE MALT1
申请人:JANSSEN BIOTECH INC
公开号:WO2018119036A1
公开(公告)日:2018-06-28
Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.